PRESS RELEASE
News
-
-
PRESS RELEASE
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
Transgene completes patient randomization in Phase 2 of clinical trial for TG4050 in adjuvant treatment of head and neck cancer. Top-line results expected by Q1 2028 -
PRESS RELEASE
The Burkhalter Group exceeds expectations once again by posting excellent results for the 2025 financial year
Burkhalter Group exceeds expectations in 2025 with strong financial performance, proposing a dividend increase and targeting acquisitions. Focus on sustainability and positive outlook for 2026 -
-
-
PRESS RELEASE
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE)
BioVersys AG and partners publish pre-clinical development data of AlpE in Nature Communications, showcasing unique Mechanism of Action targeting drug-resistance in tuberculosis -
-
-
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU for young children with chronic spontaneous urticaria, expanding treatment options to address type 2 inflammation
